Why BioStem Technologies, Inc.’s (BSEM) Stock Is Down 5.99%
As of Tuesday, October 06, BioStem Technologies, Inc.’s BSEM share price has dipped by 5.99%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a human connective tissue matrix compromised of amniotic tissue intended for wound covering; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
Commentary & Analysis
Why BioStem Technologies, Inc.’s (BSEM) Stock Is Down 7.82%
As of Friday, October 02, BioStem Technologies, Inc.’s BSEM share price has dipped by 7.82%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why BioStem Technologies, Inc.’s (BSEM) Stock Is Down 13.45%
As of Wednesday, September 30, BioStem Technologies, Inc.’s BSEM share price has dipped by 13.45%, which has investors questioning if this is right time to buy.Jenna Brashear
Why BioStem Technologies, Inc.’s (BSEM) Stock Is Down 15.93%
As of Wednesday, September 30, BioStem Technologies, Inc.’s BSEM share price has dipped by 15.93%, which has investors questioning if this is right time to buy.Jenna Brashear
Why BioStem Technologies, Inc.’s (BSEM) Stock Is Down 6.28%
As of Monday, September 28, BioStem Technologies, Inc.’s BSEM share price has dipped by 6.28%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | BSEM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $45.9 | $538.3 | 15% |
|
| Shares Out (Mil) | 17.3 | 42.8 | 28% |
|
| Institutional Ownership | na | 82.8% | na |
|
| Float (Mil) | na | 44.5 | na |
|
| Beta | 0.26 | 0.70 | 16% |
|
| Avg Daily Volume (000s) | 158 | 371 | 40% |
|
| Price Change (52-week) |
(50.2%) | 58.2% | 18% |
|
| Growth | BSEM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 139.7% | 6.1% | 99% |
|
| Net Income (5yr) | (10.5%) | (2.0%) | 29% |
|
| EPS (5yr) | 18.9% | 15.0% | 66 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 47.6% | (15.1%) | 93% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | BSEM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $35 | $416 | 17% |
|
| Net Income (TTM) (Mil) | ($28) | ($11) | 21% |
|
| EPS (TTM) | ($1.671) | ($0.700) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($6) | ($7) | 24% |
|
| Net Cash Flow (TTM) (Mil) | na | $6 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | $65 | $494 | 18% |
|
| Valuation | BSEM | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.59 | 2.29 | 44% |
|
| P/E | na | 17.3 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | BSEM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 79.9% | 69.4% | 89% |
|
| Net Margin | (81.8%) | 3.2% | 9% |
|
| ROA | (35.1%) | (22.2%) | 15% |
|
| ROE | (74.7%) | (21.0%) | 12% |
|
| Liabilities to Assets | 43.4% | 33.9% | 34% |
|
| F-Score | 2 | 3 | 7% |
|
BioStem Technologies, Inc. did not pass any screens on 10/6/2026.
